What is the ROE (Return on Equity) of ESSA Pharma this year?
The ROE of ESSA Pharma this year is -0.18 undefined.
ESSA Pharma ROE 2024
ESSA Pharma ROE
-0.18
ESSA Pharma Dividend yield
Ticker
EPIX
ISIN
CA29668H7085
WKN
A2JKQ4
In 2024, ESSA Pharma's return on equity (ROE) was -0.18, a -13.1% increase from the -0.21 ROE in the previous year.
ESSA Pharma Aktienanalyse
What does ESSA Pharma do?
ESSA Pharma Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of prostate cancer and other types of cancer. The company is headquartered in Vancouver, Canada and was founded in 2009. The history of ESSA Pharma Inc begins with the discovery of a new approach to treating prostate cancer by the company's founders. They discovered that a combination of an androgen receptor inhibitor and a NEDDylation signaling inhibitor could offer a new and effective approach to treating prostate cancer. Based on this discovery, they founded ESSA Pharma Inc to further develop this therapy. ESSA Pharma Inc's business model is based on the discovery, development, and commercialization of therapies for the treatment of prostate cancer and other types of cancer. The company has a pipeline of products in various clinical phases aimed at effectively combating prostate cancer and other types of cancer. ESSA Pharma Inc operates in two main divisions: research and development, and marketing and sales. The company's research and development department is dedicated to identifying and developing new compounds tailored to the specific needs of patients with prostate cancer. The company also works closely with researchers and physicians to test the efficacy of its products in treatment protocols and clinical practice. The second division of ESSA Pharma Inc deals with the marketing and sales of its products. Here, the company works closely with pharmaceutical manufacturers and other companies to market and sell its products worldwide. The company also has its own sales department that serves customers worldwide. ESSA Pharma Inc currently offers several products in different stages of clinical trials. These include EPI-506, an androgen receptor inhibitor currently being used in a Phase 1 study for the treatment of prostate cancer, and EPI-7386, a NEDDylation signaling inhibitor currently in a Phase 1 study for the treatment of prostate cancer. In addition, ESSA Pharma Inc has formed partnerships with other companies to further develop its technology platform and pipeline of cancer therapies. For example, the company is collaborating with Bayer Healthcare to advance the development of EPI-7386. Overall, ESSA Pharma Inc is an innovative and emerging biotech company focused on the development of therapies for the treatment of prostate cancer and other types of cancer. The company is pursuing an ambitious strategy and has already achieved promising results in the development of new compounds for the treatment of prostate cancer. ESSA Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding ESSA Pharma's Return on Equity (ROE)
ESSA Pharma's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing ESSA Pharma's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
ESSA Pharma's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in ESSA Pharma’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about ESSA Pharma Stock
How has the Return on Equity (ROE) of ESSA Pharma developed compared to the previous year?
The ROE of ESSA Pharma has increased by -13.1% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of ESSA Pharma?
A high ROE indicates that ESSA Pharma generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of ESSA Pharma?
A low ROE can indicate that ESSA Pharma is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of ESSA Pharma affect the company?
A change in ROE (Return on Equity) of ESSA Pharma can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of ESSA Pharma?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of ESSA Pharma?
Some factors that can influence ESSA Pharma's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does ESSA Pharma pay?
Over the past 12 months, ESSA Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ESSA Pharma is expected to pay a dividend of 0 USD.
What is the dividend yield of ESSA Pharma?
The current dividend yield of ESSA Pharma is .
When does ESSA Pharma pay dividends?
ESSA Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ESSA Pharma?
ESSA Pharma paid dividends every year for the past 0 years.
What is the dividend of ESSA Pharma?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ESSA Pharma located?
ESSA Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von ESSA Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ESSA Pharma from 5/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/30/2024.
When did ESSA Pharma pay the last dividend?
The last dividend was paid out on 5/30/2024.
What was the dividend of ESSA Pharma in the year 2023?
In the year 2023, ESSA Pharma distributed 0 USD as dividends.
In which currency does ESSA Pharma pay out the dividend?
The dividends of ESSA Pharma are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ESSA Pharma
Our stock analysis for ESSA Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ESSA Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
